Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 101–200 of 1,000
Collins, D. M., Madden, S. F., Gaynor, N., AlSultan, D., Gal, M. L., Eustace, A. J., Gately, K. A., Hughes, C., Davies, A. M., Mahgoub, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2007 · Cited by 86
“Tucatinib is an HER2-specific TKI recently approved in combination with trastuzumab and capecitabine for the treatment of metastatic HER2þ breast cancer (48).”
BackgroundA review of FDA approved drugs and their formulations for the treatment of breast cancer
Chaurasia, M., Singh, R., Sur, S., & Flora, S. J. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1184472 · Cited by 93
Drug resistance in breast cancer: Mechanisms and strategies for management
Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 90
How we treat patients with metastatic HER2-positive breast cancer
Marta, G. N., Martins-Branco, D. A., & de Azambuja, E. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100343 · Cited by 85
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Schlam, I. M., Tarantino, P., & Tolaney, S. M. (2022) · Cancers · doi:10.3390/cancers14163996 · Cited by 88
“It was approved in 2020, in combination with trastuzumab and capecitabine, for patients with advanced, pretreated HER2+ disease, based on the HER2CLIMB study, which showed the superiority of this triplet compared with the doublet of capecitabine and trastuzumab [22].”
BackgroundNiikura, N., Yamanaka, T., Nomura, H., Shiraishi, K., Kusama, H., YAMAMOTO, M., Matsuura, K., Inoue, K., Takahara, S., Kita, S., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00584-5 · Cited by 85
“The median IC-PFS was higher (16.1 months) compared with that reported in the HER2CLIMB trial (9.9 months) 8,9 .”
InfluentialLee, A. (2020) · Drugs · doi:10.1007/s40265-020-01340-w · Cited by 80
Targeting HER2 expression in cancer: New drugs and new indications
Vranić, S., Bešlija, S., & Gatalica, Z. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2020.4908 · Cited by 91
Brain metastases: An update on the multi-disciplinary approach of clinical management
Mitchell, D. K., Kwon, J. H., Kubica, P. A., Huff, W. X., O'Regan, R. M., & Dey, M. (2021) · Neurochirurgie · doi:10.1016/j.neuchi.2021.04.001 · Cited by 86
Zeng, X., Shi, G., He, Q., & Zhu, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00268-9 · Cited by 85
Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer
Almstedt, K., Heimes, A.-S., Kappenberg, F., Battista, M. J., Lehr, H., Krajnak, S., Lebrecht, A., Gehrmann, M. C., Stewen, K., Brenner, W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.06.012 · Cited by 79
Breast cancer brain metastasis: Current evidence and future directions
Sun, H., Xu, J., Dai, S., Ma, Y., & Sun, T. (2022) · Cancer Medicine · doi:10.1002/cam4.5021 · Cited by 84
Clark, A. S., Yau, C. S. F., Wolf, D. M., Petricoin, E. F., Veer, L. V. ‘., Yee, D., Moulder, S. L., Wallace, A. M., Chien, A. J., Isaacs, C. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26019-y · Cited by 76
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 82
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 79
“Tucatinib is a potent, highly selective inhibitor of the kinase domain of HER2 and minimally inhibits the EGFR receptor, which in theory should decrease toxicity [2].”
BackgroundInfluentialAnti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Stanowicka-Grada, M., & Senkus, E. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01137-5 · Cited by 79
Rubin, E., Shan, K. S., Dalal, S., Vu, D. U. D., Guaqueta, D. C., Naraine, A. M., & Ergle, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021064 · Cited by 85
“In terms of adverse effects, there was an increased risk of diarrhea and transaminitis in the tucatinib–combination when compared to the placebo–combination group [109].”
BackgroundSystemic therapy for metastatic HER2-positive breast cancer
Bredin, P., Walshe, J. M., & Denduluri, N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.008 · Cited by 81
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
Wu, X., Yang, H., Yu, X., & Qin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1012552 · Cited by 94
Ohba, A., Morizane, C., Ueno, M., Kobayashi, S., Kawamoto, Y., Komatsu, Y., Ikeda, M., Sasaki, M., Okano, N., Furuse, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0214 · Cited by 79
Multilevel Mechanisms of Cancer Drug Resistance
Roszkowska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212402 · Cited by 85
An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy
Alharbi, K. S., Shaikh, M. A. J., Afzal, O., Altamimi, A. S. A., Almalki, W. H., Alzarea, S. I., Kazmi, I. A., Al-Abbasi, F. A., Singh, S. K., Dua, K., et al. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110108 · Cited by 77
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Conlon, N. T., Kooijman, J. J., van Gerwen, S. J. C., Mulder, W. R., Zaman, G. J. R., Diala, I., Eli, L. D., Lalani, A. S., Crown, J. P., & Collins, D. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01257-x · Cited by 76
“Three HER2-targeted TKIs, lapatinib (Tykerb/Tyverb), neratinib (Nerlynx), and tucatinib (Tukysa), have been approved for the treatment of HER2+ breast cancer after progression following HER2-targeted therapy.(7,9,10) These drugs are all orally available and target the kinase domain of HER2.”
BackgroundMolecular Chaperone GRP94/GP96 in Cancers: Oncogenesis and Therapeutic Target
Duan, X., Iwanowycz, S., Ngoi, S. M., Hill, M., Zhao, Q., & Liu, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629846 · Cited by 76
Oberkampf, F., Gutierrez, M., Trabelsi‐Grati, O., Rhun, É. L., Trédan, O., Turbiez, I., Kadi, A., Dubot, C., Taillibert, S., Vacher, S., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac180 · Cited by 74
Rethinking breast cancer follow-up based on individual risk and recurrence management
Rose, F. D., Meduri, B., Santis, M. C. D., Ferro, A., Marino, L., Colciago, R. R., Gregucci, F., Vanoni, V., Apolone, G., Cosimo, S. D., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102434 · Cited by 73
Self-citationChinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 81
“The SOPHIA study (34) included patients with advanced breast cancer who had received at least two prior lines of anti-HER2-targeted therapy but no more than three total lines.”
Mitani, S., & Kawakami, H. (2020) · Cancers · doi:10.3390/cancers12020400 · Cited by 73
“6 months, respectively, with the primary end point thus being met [56].”
BackgroundTyrosine kinase inhibitors in breast cancer (Review)
Iancu, G., Şerban, D., Badiu, C. D., Tanasescu, C. A. H., TUDOSIE, M. D., Tudor, C., Costea, D. O., Zgura, A. F., Iancu, R. C., & Vasile, D. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11037 · Cited by 71
“The combination of tucatinib with trastuzumab and capecitabine in HER2‐positive metastatic BC provided clear benefits in the PFS and OS rates when compared with the placebo combination (46).”
BackgroundTargeting fatty acid oxidation enhances response to HER2-targeted therapy
Nandi, I., Ji, L., Smith, H. W., Avizonis, D. Z., Papavasiliou, V., Lavoie, C. A., Pacis, A., Attalla, S. S., Sanguin‐Gendreau, V., & Muller, W. J. (2024) · Nature Communications · doi:10.1038/s41467-024-50998-3 · Cited by 73
“…HER2+ breast cancer are candidates for monoclonal antibody (mAb) therapies that interfere with HER2 by binding to its extracellular domains, including Trastuzumab(Herceptin) and Pertuzumab(Perjeta), as well astyrosine kinase inhibitors (TKIs) such as Lapatinib, Neratinib and Tucatinib 20 – 23 .”
BackgroundHER family in cancer progression: From discovery to 2020 and beyond
Kumar, R., George, B., Campbell, M. R., Verma, N., Paul, A. M., Melo-Alvim, C., Ribeiro, L., Pillai, M. R., Costa, L., & Moasser, M. M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.001 · Cited by 70
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
Sirhan, Z., Thyagarajan‐Sahu, A., & Sahu, R. P. (2022) · Military Medical Research · doi:10.1186/s40779-022-00401-3 · Cited by 81
“Tucatinib + trastuzumab + capecitabine [33] ALT/AST To evaluate the therapeutic responses of tucatinib vs.”
BackgroundInfluentialMolecular Pathways and Mechanisms of HER2 in Cancer Therapy
Raghav, K. P. S., & Moasser, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0283 · Cited by 76
Hurvitz, S. A., Saura, C., Oliveira, M., Trudeau, M., Moy, B., Delaloge, S., Gradishar, W. J., Kim, S., Haley, B., Ryvo, L., et al. (2021) · The Oncologist · doi:10.1002/onco.13830 · Cited by 68
“HER2CLIMB compared tucatinibtrastuzumab-capecitabine with placebo-trastuzumabcapecitabine in patients with HER2-positive metastatic breast cancer previously treated with HER2-directed therapy and was positive both for PFS and OS in the intention-to-treat and brain metastases populations [26].”
BackgroundSelf-citationBreast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Im, S., Gennari, A., Park, Y. H., Kim, J. H., Jiang, Z., Gupta, S., Fadjari, T. H., Tamura, K., Mastura, M. Y., Abesamis-Tiambeng, M. L. T., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101541 · Cited by 72
“breast cancer, including those with brain metastases, who have received prior anti-HER2-based regimens in the metastatic setting.(87,123) The kinase inhibitor neratinib in combination with capecitabine has shown modest PFS and OS gains over lapatinibecapecitabine but significantly improved PFS and time to intervention…”
BackgroundSelf-citationWilding, B., Scharn, D., Böse, D., Baum, A., Santoro, V., Chetta, P., Schnitzer, R., Botesteanu, D., Reiser, C., Kornigg, S., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00412-y · Cited by 65
Wang, J., Liu, Y., Zhang, Q., Li, W., Feng, J., Wang, X., Fang, J., Han, Y., & Xu, B. (2024) · 癌症:英文版 · doi:10.1002/cac2.12577 · Cited by 68
Neratinib for HER2-positive breast cancer with an overlooked option
Guo, L., Shao, W., Zhou, C., Yang, H. J., Yang, L., Cai, Q., Wang, J., Shi, Y., Huang, L., & Zhang, J. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00736-0 · Cited by 59
Precision medicine in breast cancer: From clinical trials to clinical practice
Crimini, E., Repetto, M., Aftimos, P. G., Botticelli, A., Marchetti, P., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102223 · Cited by 61
Self-citationThe role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer
Du, F. L., Dieras, V. C., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.026 · Cited by 60
Self-citationFDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 59
“Patients with HER2 + BC who have disease progression after prior therapy with multiple HER2-targeted drugs may benefit from these TKIs used with or without trastuzumab [27,28].”
BackgroundZhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 63
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
Holloway, R. W., & Marignani, P. A. (2021) · Cancers · doi:10.3390/cancers13122922 · Cited by 61
“In HER2CLIMB, a phase II clinical trial, tucatinib–trastuzumab–capecitabine combination therapy for HER2-positive breast cancer showed a higher ORR and median PFS than the placebo–trastuzumab–capecitabine group (Table 1); however, this was associated with a high incidence of adverse effects [56].”
BackgroundKuipers, H., de Bitter, T. J. J., de Boer, M. T., van der Post, R. S., Nijkamp, M. W., de Reuver, P. R., Fehrmann, R. S. N., & Hoogwater, F. J. H. (2021) · Cancers · doi:10.3390/cancers13215257 · Cited by 57
“ERBB2 * 1 Breast cancer Ado-trastuzumab emtansine 173/397 (44%) [88] Lapatinib + letrozole 31/111 (28%) [89] Lapatinib + capecitabine 36/163 (22%) [90] Margetuximab + chemotherapy 67/266 (25%) [91] Neratinib 34/117 (29%) [92] Trastuzumab 30/114 (26%) [93] Trastuzumab + pertuzumab + chemotherapy 275/343 (80%) [94] Tras…”
Zagouri, F., Zoumpourlis, P., Rhun, É. L., Bartsch, R., Zografos, E., Apostolidou, K., Dimopoulos, M. A., & Preusser, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102046 · Cited by 57
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 64
A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt, M. G., Naghavi‐Behzad, M., & Vogsen, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.004 · Cited by 59
Lorusso, G., Wyss, C. B., Kuonen, F., Vannini, N., Billottet, C., Duffey, N., Pineau, R., Lan, Q., Wirapati, P., Barras, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8933 · Cited by 57
“DISCUSSION Despite some recent progress (5, 6), the management of brain metastasis remains an outstanding therapeutic challenge calling for new actionable targets to translate into clinical testing, including in breast cancer (8–10).”
BackgroundTapia, M., Hernándo, C., Martínez, M. T., Burgués, O., Tebar, C., Lameirinhas, A., Ágreda‐Roca, A., Torres‐Ruiz, S., Garrido‐Cano, I., Lluch, A. M., et al. (2023) · Cancers · doi:10.3390/cancers15184522 · Cited by 60
“However, only a small number of patients presented grade III or higher adverse events [65].”
BackgroundTrastuzumab Deruxtecan for HER2+ Advanced Breast Cancer
Lee, J., & Park, Y. H. (2021) · Future Oncology · doi:10.2217/fon-2021-0550 · Cited by 55
Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
Dent, S. F., Morse, A. M., Burnette, S., Guha, A., & Moore, H. M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01114-x · Cited by 56
“Tucatinib [23] • Unresectable/metastatic HER2 + breast cancer in combination with Trastuzumab and capecitabine after 1 prior anti-HER2 based regimen”
BackgroundInfluentialTesch, M. E., & Gelmon, K. A. (2020) · Drugs · doi:10.1007/s40265-020-01411-y · Cited by 55
Self-citationAndré, F., Cortés, J., Curigliano, G., Modi, S., Li, W., Park, Y. H., Chung, W.-P., Kim, S.-B., Yamashita, T., Pedrini, J. L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2347 · Cited by 56
Self-citationWu, Q., Liao, W., Zhang, M., Huang, J., Zhang, P., & Li, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01336 · Cited by 51
“Besides, patients in both groups received trastuzumab (8 mg/kg for initial therapy followed by 6 mg/kg for maintenance) on day 1 and capecitabine (1,000 mg/m2) twice daily on days 1–14 repeated every 3 weeks (15).”
BackgroundMethodInfluentialFong, S. S., Foo, Y. Y., Saw, W. S., Leo, B. F., Teo, Y. Y., Chung, I., Goh, B. T., Misran, M., Imae, T., Chang, C.-C., et al. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s337093 · Cited by 50
“Although antimetastatic agents may extend the progression-free survival period in patients with metastatic disease, adverse effects have been correlated to the random drug dissemination and use that is limited to a “dosed until unacceptable toxicity” basis in clinical settings.(49,50) Nanocarriers have been frequently…”
BackgroundBergeron, A., Bertaut, A., Beltjens, F., Charon‐Barra, C., Amet, A., Jankowski, C., Desmoulins, I., Ladoire, S., & Arnould, L. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02287-x · Cited by 58
Servetto, A., Formisano, L., & Arteaga, C. L. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188595 · Cited by 57
Ligorio, F., Pellegrini, I., Castagnoli, L., Vingiani, A., Lobefaro, R., Zattarin, E., Santamaria, M., Pupa, S. M., Pruneri, G., de Braud, F., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.023 · Cited by 51
Zhao, L., Liu, C., Xing, Y. T., He, J., O’Doherty, J., Huang, W., & Zhao, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00569 · Cited by 51
Hackshaw, M. D., Danysh, H. E., Henderson, M., Wang, E., Tu, N., Islam, Z., Ladner, A., Ritchey, M. E., & Salas, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08708-5 · Cited by 49
“A recent randomized controlled trial found the addition of tucatinib compared with placebo to trastuzumab and capecitabine regimens improved progression-free survival and OS [47].”
BackgroundTargeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
Ferrando‐Díez, A., Felip, E., Pous, A., Bergamino, M. A., & Vila, M. M. (2022) · Cancers · doi:10.3390/cancers14143305 · Cited by 51
“Beyond these, new agents have also shown increased progression-free survival (PFS) and overall survival (OS) in the metastatic setting, such as trastuzumabderuxtecan (T-DXd) or tucatinib in combination with capecitabine and trastuzumab [10,11].”
BackgroundAlsalme, A., Pooventhiran, T., Al‐Zaqri, N., Rao, D. J., Rao, S. S., & Thomas, R. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04603-1 · Cited by 48
Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Gámez-Chiachio, M., Sarrió, D., & Moreno‐Bueno, G. (2022) · Cancers · doi:10.3390/cancers14184543 · Cited by 53
Sachdev, J. C., Münster, P. N., Northfelt, D., Han, H. S., Ma, C. X., Maxwell, F., Wang, T. L., Belanger, B., Zhang, B., Moore, Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05995-7 · Cited by 48
Self-citationLeptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
Pellerino, A., Brastianos, P. K., Rudà, R., & Soffietti, R. (2021) · Cancers · doi:10.3390/cancers13122888 · Cited by 50
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Waks, A. G., Martínez‐Sáez, O., Tarantino, P., Brasó‐Maristany, F., Pascual, T., Cortés, J., Tolaney, S. M., & Prat, A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00939-2 · Cited by 52
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 53
How we treat HER2-positive brain metastases
Stavrou, E., Winer, E. P., & Lin, N. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100256 · Cited by 49
“001).(18) In an exploratory analysis among the patients with brain metastases, the median intracranial confirmed objective response rate was 47% versus 20%, P 1⁄4 0.”
BackgroundSelf-citationSynthetic Approaches to the New Drugs Approved During 2020
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Mahapatra, S., Carney, D. W., Lindsey, E. A., DeForest, J. C., France, S. P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00710 · Cited by 46
The Role of Microglia in Brain Metastases: Mechanisms and Strategies
Feng, Y., Hu, X., Zhang, Y., & Wang, Y. (2024) · Aging and Disease · doi:10.14336/ad.2023.0514 · Cited by 51
Metzger, O., Leone, J. P., Li, T., Tan‐Wasielewski, Z., Trippa, L., Barry, W. T., Younger, J., Lawler, E., Walker, L. N., Freedman, R. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.014 · Cited by 46
Self-citationLocoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
Reinhorn, D. J., Mutai, R., Yerushalmi, R., Moore, A., Amir, E., & Goldvaser, H. (2021) · The Breast · doi:10.1016/j.breast.2021.05.003 · Cited by 53
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 52
Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer
Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316607 · Cited by 49
“The aberrant activation of CDK4/6 and PI3K signaling may also be involved in HER-2-positive metastatic breast cancer [125–127].”
BackgroundNew Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Mezni, E., Vicier, C., Guérin, M., Sabatier, R., Bertucci, F., & Gonçalvès, A. (2020) · Cancers · doi:10.3390/cancers12061573 · Cited by 46
“HER2CLIMB was a phase III trial, which evaluates tucatinib associated with capecitabine and trastuzumab in heavily pretreated HER-positive BC, including patients with brain metastasis (NCT02614794) [59].”
BackgroundLeptomeningeal metastatic disease: new frontiers and future directions
Ozair, A., Wilding, H. E., Bhanja, D., Mikolajewicz, N., Glantz, M., Grossman, S. A., Sahgal, A., Rhun, É. L., Weller, M., Weiß, T., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00970-3 · Cited by 48
“This phenomenon continues to occur in trials of ADCs for brain metastases, which have explicitly excluded patients with LMD 139,140 or did not have LMD-specific data reported when results were published 141,142 , despite increasing evidence of the intracranial efficacy of this therapeutic class.”
Valle, I., Grinda, T., Antonuzzo, L., & Pistilli, B. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00829-5 · Cited by 52
Landscape of combination therapy trials in breast cancer brain metastasis
Fares, J., Kanojia, D., Rashidi, A., Ulasov, I. V., & Lesniak, M. S. (2020) · International Journal of Cancer · doi:10.1002/ijc.32937 · Cited by 44
Ramamoorthi, G., Kodumudi, K. N., Gallen, C., Zachariah, N. N., Basu, A. B., Albert, G. K., Beyer, A., Snyder, C., Wiener, D. A., Costa, R. L. B., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.02.004 · Cited by 43
Peterson, L. E. (2020) · African Journal of Pharmaceutical Sciences · doi:10.2139/ssrn.3599426 · Cited by 45
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 44
Bansal, I., Pandey, A. K., & Ruwali, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1244597 · Cited by 44
“The FDA approved tucatinib in April 2020 after the trial showed significant improvements in overall survival rate and progression-free survival (Murthy et al., 2020).”
BackgroundMansouri, A., Ozair, A., Bhanja, D., Wilding, H. E., Mashiach, E., Haque, W. Z., Mikolajewicz, N., Filho, L. D. M., Mahase, S. S., Machtay, M. X., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01013-1 · Cited by 53
Kim, J. S., & Kim, I. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936117 · Cited by 47
Effect of polyphenols on HER2-positive breast cancer and related miRNAs: Epigenomic regulation
Elexpuru-Zabaleta, M., Forbes-Hernández, T. Y., Simal‐Gándara, J., Quiles, J. L., Cianciosi, D., Bullón, B., Giampieri, F., & Battino, M. A. (2020) · Food Research International · doi:10.1016/j.foodres.2020.109623 · Cited by 44
Hart, V., Gautrey, H., Kirby, J. A., & Tyson-Capper, A. J. (2020) · Oncotarget · doi:10.18632/oncotarget.27789 · Cited by 44
“com in patients who have previously received trastuzumab, pertuzumab, T-DM1 and lapatinib [70, 71].”
BackgroundTrastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
Pérez-García, J. M., Garrigós, L., Gión, M., Janne, P. A., Shitara, K., Siena, S., & Cortés, J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1890710 · Cited by 43
“5%) of grade ≥3 were more common in the tucatinib group [47] AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; DCR, disease control rate; GC, gastric cancer; HER, human epidermal growth factor receptor; HR, hazard ratio; IHC, immunohistochemistry; ISH, in sit…”
BackgroundInfluentialKörfer, J., Lordick, F., & Hacker, U. T. (2021) · Cancers · doi:10.3390/cancers13205216 · Cited by 46
“Also, several pan-HER TKIs like Tucatinib showing already efficacy in extensively pretreated HER2+ breast cancer patients and has received market authorization for this indication in combination with Trastuzumab and Capecitabine [44] or Neratinib, which was investigated in in vitro experiments using gastric cancer cel…”
BackgroundInfluentialAiming at a Tailored Cure for ERBB2 -Positive Metastatic Breast Cancer: A Review
Tarantino, P., Curigliano, G., Parsons, H. A., Lin, N., Krop, I. E., Mittendorf, E. A., Waks, A. G., Winer, E. P., & Tolaney, S. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6597 · Cited by 44
Self-citationVanhoutte, T., & Sprangers, B. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad011 · Cited by 44
Dhiman, R., Bazad, N., Mukherjee, R., Himanshu, Gunjan, Leal, E., Ahmad, S., Kaur, K., Raj, V. S., Chang, C.-M., et al. (2024) · Discover Nano · doi:10.1186/s11671-024-04086-6 · Cited by 40
“Approved by the FDA, tucatinib, when combined with trastuzumab and capecitabine, improved progression-free survival (PFS) and overall survival (OS) in advanced HER2 + metastatic BC, as shown in the phase II HER2CLIMB trial [112].”
BackgroundTurner, N. C., Saura, C., Aftimos, P. G., van den Tweel, E., Oesterholt, M., Koper, N. P., Colleoni, M. A., Kaczmarek, E., Punie, K., Song, X., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00529 · Cited by 42
“5 17-20 Despite the improved ef fi cacy of newer agents, most patients still develop progressive and/or refractory disease during/ after HER2-targeted therapy, although HER2 expression persists.”
Self-citationHu, X., Zhang, Q., Wang, L., Zhang, J., Ouyang, Q., Wang, X., Li, W., Xie, W., Tong, Z., Wang, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02149-3 · Cited by 46
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 43
Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
Almstedt, K., Krauthauser, L., Kappenberg, F., Wagner, D., Heimes, A.-S., Battista, M. J., Anić, K., Krajnak, S., Lebrecht, A., Schwab, R. M., et al. (2023) · Cancers · doi:10.3390/cancers15051413 · Cited by 45
“In the event of progression, tyrosine kinase inhibitors such as lapatinib or tucatinib showed efficacy in HER2-positive breast carcinoma [5,6].”
BackgroundManagement of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Pernas, S., & Tolaney, S. M. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00020 · Cited by 40
Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3247 · Cited by 37
Molecular perspective on targeted therapy in breast cancer: a review of current status
Cetinkaya, B. D., & Avcı, Ç. B. (2022) · Medical Oncology · doi:10.1007/s12032-022-01749-1 · Cited by 41
Tumour invasion and dissemination
Lusby, R., Dunne, P. D., & Tiwari, V. K. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220452 · Cited by 32
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.